Larimar Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a U.S.-listed clinical-stage biotechnology company traded on the NASDAQ under the ticker LRMR. The company is headquartered in Bala Cynwyd, Pennsylvania, in the Philadelphia area, and is organized in Delaware. It was founded in 2005 as Zafgen, Inc. and later became Larimar Therapeutics following a merger with Chondrial Therapeutics. Today, Larimar is positioned as a highly focused rare-disease biotech, with its strategy centered on a narrow but potentially value-creating scientific and regulatory pathway. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm?utm_source=openai)) Larimar’s core business is the development of nomlabofusp, a frataxin replacement therapy designed for Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease with limited treatment options. The company’s scientific thesis is that restoring frataxin deficiency may address the underlying biology of the disease rather than only managing symptoms. Larimar’s historical platform has also relied on cell-penetrating peptide technology, which underpins its approach to delivering protein therapeutics to mitochondria. This makes the company a classic development-stage biotech, where the value proposition depends on clinical proof-of-concept, regulatory execution, manufacturing readiness, and eventual commercialization potential. ([larimartx.com](https://larimartx.com/?utm_source=openai)) From a competitive standpoint, Larimar operates in a concentrated rare-disease segment where differentiation is driven by mechanism, clinical data, and regulatory positioning. The company’s lead asset has been advancing through registrational activities, and in February 2026 Larimar announced that the FDA granted nomlabofusp Breakthrough Therapy Designation for adults and children with FA. Larimar has also said that its discussions with the FDA support the use of skin frataxin as a surrogate endpoint in a planned BLA submission seeking accelerated approval, which it has guided for June 2026. Those updates are important because they suggest a clearer regulatory path, although the investment case remains highly dependent on execution and trial outcomes. ([investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai)) Geographically, the company’s footprint remains primarily U.S.-based, with corporate and operational activity run from Bala Cynwyd, Pennsylvania. Larimar is not yet a commercial-stage multinational; its presence is largely clinical, regulatory, and manufacturing-preparatory rather than broad-based global sales. Recent milestones include the Breakthrough Therapy Designation, ongoing open-label study updates, data publication supporting skin as a surrogate tissue for frataxin measurement, and capital raising activity in 2025 and early 2026 to support the next development phase. For investors, LRMR is best viewed as a high-risk, high-catalyst biotech name on the NASDAQ in the United States, with upside tied to whether nomlabofusp can become a first-in-class disease-modifying therapy for FA. ([investors.larimartx.com](https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-announces-fda-breakthrough-therapy?utm_source=openai))